Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis
暂无分享,去创建一个
R. Pazdur | L. Amiri-Kordestani | Tatiana M. Prowell | R. Sridhara | Shenghui Tang | J. Beaver | M. Royce | G. Ison | E. Bloomquist | C. Osgood | S. Wedam | Joyce Cheng | Jennifer J. Gao | D. Krol